GRK2 Antibody (YA2949)
(Synonyms: GRK2; BARK1; FLJ16718; BETA-ARK1; ADRBK1)GRK2 Antibody (YA2949) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GRK2.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IP
-
Reactivity :
Human
-
Formulation:
Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
IP
IP: Immunoprecipitation
|
|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:20 |
Product Details
GRK2 Antibody (YA2949) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GRK2.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 80 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 80 kDa
A synthetic peptide of human GRK2
Endogenous
Affinity Purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
GRK2 (G protein-coupled receptor kinase 2) is a ubiquitously expressed serine/threonine kinase that functions as a central regulator of G protein-coupled receptor (GPCR) signaling through receptor phosphorylation, β-arrestin recruitment, receptor desensitization, and internalization[1][2]. Mechanistically, GRK2 acts beyond canonical GPCR regulation by interacting with multiple signaling proteins, including Gαq, MAPK-associated pathways, and non-receptor substrates, thereby serving as a multifunctional signaling hub that integrates cellular responses to extracellular stimuli[3][4]. Through these activities, GRK2 influences diverse biological processes such as inflammation, migration, metabolism, and cardiovascular homeostasis[4][5]. In disease contexts, elevated GRK2 expression has been consistently associated with heart failure, cardiovascular dysfunction, obesity-related metabolic disorders, and insulin resistance, while genetic or pharmacological attenuation of GRK2 activity shows protective effects in experimental models[5][6]. Compared with related isoforms, GRK2 belongs to the ubiquitously expressed GRK2 subfamily together with GRK3, yet exhibits distinct regulatory interactions and has emerged as the most extensively studied isoform in cardiovascular and metabolic pathophysiology[1][5]. For experimental applications, GRK2 has attracted considerable interest as a therapeutic target, and multiple small-molecule inhibitors have been developed to suppress its kinase activity or interfere with its signaling functions, providing valuable tools for mechanistic studies and preclinical disease research[6][7].
-
Subcellular Localization
Cytoplasm; Cell membrane; Postsynapse; Presynapse
-
Expression
Tissue_specificity:Expressed in peripheral blood leukocytes -
Subunit
Interacts with, and phosphorylates chemokine-stimulated CCR5 (PubMed:10085131). Interacts with ARRB1 (PubMed:9501202). Interacts with LPAR1 and LPAR2 (PubMed:19306925).
-
SwissProt ID
-
Synonyms
GRK2; BARK1; FLJ16718; BETA-ARK1; ADRBK1
-
Research Field
Neuroscience
Documentation
[1]. Watari K, et al. Multiple functions of G protein-coupled receptor kinases. J Mol Signal. 2014 Mar 6;9(1):1. [Content Brief]
[2]. Evron T, et al. GRK2: multiple roles beyond G protein-coupled receptor desensitization. Trends Pharmacol Sci. 2012 Mar;33(3):154-64. [Content Brief]
[3]. Carman CV, et al. Selective regulation of Galpha(q/11) by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem. 1999 Nov 26;274(48):34483-92. [Content Brief]
[4]. Penela P, et al. G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub. Cell Mol Life Sci. 2019 Nov;76(22):4423-4446. [Content Brief]
[5]. Kim MJ, et al. Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS? Cells. 2018 Dec 20;8(1):1. [Content Brief]
[7]. Guccione M, et al. G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives. J Med Chem. 2016 Oct 27;59(20):9277-9294. [Content Brief]